{"id":389046,"date":"2020-11-27T08:12:14","date_gmt":"2020-11-27T13:12:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=389046"},"modified":"2020-11-27T08:12:14","modified_gmt":"2020-11-27T13:12:14","slug":"ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/","title":{"rendered":"CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy\u2019s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell &amp; Gene Therapies"},"content":{"rendered":"<div class=\"mw_release\">\n<p>MALVERN, Pa., Nov.  27, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JLBgHPu8dQfLzX28dJwkWKwvKoRUUSV6sdu3HAXhsR9lT0CpgDn_TPzifvdS-VJCHGsN_xt3Jrr-vYKSB3n9IQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Ocugen, Inc.<\/u><\/a> (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0gjvpApw8sd7cdphE-FVFhrOcSTvc4mQYon-W7xUR0BMmMDFTRErDxIxaN32Xq3XykYyYwcPaPTQ-gIUm9HwhA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Dr.<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xgdbsdiuxyEClQNXFjIwGi9ZJ012wp-uSc-kUMhYCSPjibmMjatb8e1qPjD6upA7Z0zuC-Cr00f_UXXOCUKB0qes9fYIiKl-jMaZFNxbtj0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"> Shankar Musunuri<\/a>, Chairman, CEO, and Co-Founder of Ocugen, will speak on \u201cThe Promise of Cell &amp; Gene Therapies: Regulatory and Reimbursement Roadblocks\u201d at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KQB1rnhWc7-VotS-S26i0FBdFBSpU71Ic7CN7xzXDk8bEvSdc_UK1IeZml52bmqkN4DV1VD9xC0oDnJcWmwl9-GXhCJSBQyEIv0hw7gSUYmjLgLwB1sVb_8dFTvzDw3v\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Xconomy\u2019s<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AWYMBUg08AF6hQb8qTB-R57afgog6LGzvJW0d9BwbHyp5PREqr7RMkpezXz8h2hQlqfciuXCt_UUUanEfYrDLx3JuRlBaWuiBrFkXopaAOPl_pL8XM4CQi6ennyPzsV49h_pHdpEN5VkmoyhbyokrXn4sY6iCbn24bvq1twQRM8_wimMC1UUHZ-i-e15d3lEA21g9Xjo5Nwqhx-w9XxK_g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"> Xcelerating Life Sciences New York &amp; Philadelphia Virtual Event<\/a> on December 3 at 10:30 a.m. This panel will be moderated by Theresa Lavoie, Principal, Fish &amp; Richardson and also feature panelists, Greg White, Senior Director, Global Market Access Policy \u2013 Janssen, Pharmaceutical Companies and Snehal Naik, Global Regulatory Affair- Advanced Therapies, Janssen R&amp;D.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:12%;width:12%;min-width:12%\">\u00a0<\/td>\n<td style=\"max-width:88%;width:88%;min-width:88%\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\">\n            <strong>Presentation Details:<\/strong><br \/>\n            \n          <\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Title:<\/strong>\n          <\/td>\n<td>\u201cThe Promise of Cell &amp; Gene Therapies: Regulatory and Reimbursement Roadblocks\u201d<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Date:\u00a0<\/strong>\n          <\/td>\n<td>Thursday, December 3, 2020<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Time:<\/strong>\n          <\/td>\n<td>10:30 AM (ET)<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Location:<\/strong>\n          <\/td>\n<td>Digital<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Register<\/strong><br \/>\n            <strong>:<\/strong>\n          <\/td>\n<td>\n            <a href=\"https:\/\/xconomy.com\/xcelerating-life-sciences-new-york\/register-now-2\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/xconomy.com\/xcelerating-life-sciences-new-york\/register-now-2\/<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About Ocugen, Inc.<br \/><\/strong>Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug \u2013 \u201cone to many\u201d and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ksPGuPBUX5CugKB7ICYGsl2ADA1p9zRAG3iLn0RwBScaNsqG9JIM-9DtnjiyDsAp3sPXF3wTI4zSTou9jCWTbQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.ocugen.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Cautionary Note on Forward-Looking<\/strong><br \/>\n        <strong>Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the \u201cSEC\u201d), including the risk factors described in the section entitled \u201cRisk Factors\u201d in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p>\n        <strong>Corporate Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JLBgHPu8dQfLzX28dJwkWOlLVBkl4SHLLfwvFs8zlah265BPJPfrPcBeehv_hOEexysmQDW0-0ry5ZMzjAmAzw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n          <u>Ocugen, Inc.<\/u><br \/>\n        <\/a><br \/>\n        <br \/>Sanjay Subramanian<br \/>Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vsqg-Q4cKc1_9G9EBc-jdErITrbbqMNu5VaqGgHpRKnzUYnw6wToMLhDRCaTRg81bynHbRicUbTqz0CwbUrD8A==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">IR@Ocugen.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7z176P5WLoa6AqFF7YuCQ4QBSQ6gqTQO2jFo19kjwRG40Zu7lF-SYN063LIrSJ9zgd4Dl5Tn-JpdfRDd7D9K3tqy-oFzysDwUy4nJLOso6o=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n          <u>LaVoieHealthScience<\/u><br \/>\n        <\/a><br \/>\n        <br \/>Katie Gallagher<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-vS1RgUa2HcrHaAwFTyyuPSkCWhSt4oSchgsWSmpoivgEBSjvTFTDwq-jAXy0PV4gPauupaG4FiV21myCpuCaF_8aEnfMLyHJZvto3CSF63Fsc5TxVPaukQwG8XikSVeFUPctjiUleZ6mhcjf9ySdg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">kgallagher@lavoiehealthscience.com<\/a><br \/>+1 617-792-3937<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MzA4OCMzODQ2MjAwIzIxODQ1MTk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/9af99f5e-3077-4e56-9555-56b68387633c\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., Nov. 27, 2020 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on \u201cThe Promise of Cell &amp; Gene Therapies: Regulatory and Reimbursement Roadblocks\u201d at Xconomy\u2019s Xcelerating Life Sciences New York &amp; Philadelphia Virtual Event on December 3 at 10:30 a.m. This panel will be moderated by Theresa Lavoie, Principal, Fish &amp; Richardson and also feature panelists, Greg White, Senior Director, Global Market Access Policy \u2013 Janssen, Pharmaceutical Companies and Snehal Naik, Global Regulatory Affair- Advanced Therapies, Janssen R&amp;D. \u00a0 \u00a0 Presentation Details: Title: \u201cThe Promise of Cell &amp; Gene Therapies: Regulatory &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy\u2019s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell &amp; Gene Therapies&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-389046","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy\u2019s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell &amp; Gene Therapies - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy\u2019s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell &amp; Gene Therapies - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., Nov. 27, 2020 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on \u201cThe Promise of Cell &amp; Gene Therapies: Regulatory and Reimbursement Roadblocks\u201d at Xconomy\u2019s Xcelerating Life Sciences New York &amp; Philadelphia Virtual Event on December 3 at 10:30 a.m. This panel will be moderated by Theresa Lavoie, Principal, Fish &amp; Richardson and also feature panelists, Greg White, Senior Director, Global Market Access Policy \u2013 Janssen, Pharmaceutical Companies and Snehal Naik, Global Regulatory Affair- Advanced Therapies, Janssen R&amp;D. \u00a0 \u00a0 Presentation Details: Title: \u201cThe Promise of Cell &amp; Gene Therapies: Regulatory &hellip; Continue reading &quot;CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy\u2019s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell &amp; Gene Therapies&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-27T13:12:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MzA4OCMzODQ2MjAwIzIxODQ1MTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy\u2019s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell &amp; Gene Therapies\",\"datePublished\":\"2020-11-27T13:12:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\\\/\"},\"wordCount\":453,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MzA4OCMzODQ2MjAwIzIxODQ1MTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\\\/\",\"name\":\"CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy\u2019s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell &amp; Gene Therapies - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MzA4OCMzODQ2MjAwIzIxODQ1MTk=\",\"datePublished\":\"2020-11-27T13:12:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MzA4OCMzODQ2MjAwIzIxODQ1MTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MzA4OCMzODQ2MjAwIzIxODQ1MTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy\u2019s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell &amp; Gene Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy\u2019s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell &amp; Gene Therapies - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/","og_locale":"en_US","og_type":"article","og_title":"CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy\u2019s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell &amp; Gene Therapies - Market Newsdesk","og_description":"MALVERN, Pa., Nov. 27, 2020 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on \u201cThe Promise of Cell &amp; Gene Therapies: Regulatory and Reimbursement Roadblocks\u201d at Xconomy\u2019s Xcelerating Life Sciences New York &amp; Philadelphia Virtual Event on December 3 at 10:30 a.m. This panel will be moderated by Theresa Lavoie, Principal, Fish &amp; Richardson and also feature panelists, Greg White, Senior Director, Global Market Access Policy \u2013 Janssen, Pharmaceutical Companies and Snehal Naik, Global Regulatory Affair- Advanced Therapies, Janssen R&amp;D. \u00a0 \u00a0 Presentation Details: Title: \u201cThe Promise of Cell &amp; Gene Therapies: Regulatory &hellip; Continue reading \"CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy\u2019s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell &amp; Gene Therapies\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-27T13:12:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MzA4OCMzODQ2MjAwIzIxODQ1MTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy\u2019s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell &amp; Gene Therapies","datePublished":"2020-11-27T13:12:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/"},"wordCount":453,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MzA4OCMzODQ2MjAwIzIxODQ1MTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/","name":"CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy\u2019s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell &amp; Gene Therapies - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MzA4OCMzODQ2MjAwIzIxODQ1MTk=","datePublished":"2020-11-27T13:12:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MzA4OCMzODQ2MjAwIzIxODQ1MTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MzA4OCMzODQ2MjAwIzIxODQ1MTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomys-xcelerating-life-sciences-virtual-event-discussing-the-promise-of-cell-gene-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy\u2019s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell &amp; Gene Therapies"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=389046"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389046\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=389046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=389046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=389046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}